TY - JOUR
T1 - MYO5A::FGFR1 represents a novel fusion event in pediatric low-grade glioma
AU - Galvin, Robert T.
AU - Zheng, Cynthia
AU - Fitzpatrick, Garrett
AU - Forster, Colleen L.
AU - Sandoval-Garcia, Carolina
AU - Guillaume, Daniel
AU - Elbermawy, Ahmed
AU - Nelson, Andrew C.
AU - Özütemiz, Can
AU - Chen, Liam
AU - Moertel, Christopher L.
N1 - Publisher Copyright:
© The Author(s) 2023.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Low-grade gliomas (LGG) represent the most common type of central nervous system (CNS) neoplasm in children. Importantly, pediatric-type LGGs, affecting children and young adults, are molecularly distinct from adult-type LGGs. While the latter typically harbor IDH1 or IDH2 mutations, pediatric-type LGGs invariably involve activation of the mitogen-activated protein kinase (MAPK) cascade. While adult-type LGG often progress into higher grade gliomas over time, pediatric-type LGGs are associated with excellent overall survival of >95%. Nonetheless, they are at risk for progression many years after diagnosis and patients may suffer functional morbidity.
AB - Low-grade gliomas (LGG) represent the most common type of central nervous system (CNS) neoplasm in children. Importantly, pediatric-type LGGs, affecting children and young adults, are molecularly distinct from adult-type LGGs. While the latter typically harbor IDH1 or IDH2 mutations, pediatric-type LGGs invariably involve activation of the mitogen-activated protein kinase (MAPK) cascade. While adult-type LGG often progress into higher grade gliomas over time, pediatric-type LGGs are associated with excellent overall survival of >95%. Nonetheless, they are at risk for progression many years after diagnosis and patients may suffer functional morbidity.
KW - MYO5A:FGFR1
KW - low-grade glioma
KW - next generation sequencing
KW - pediatric
UR - http://www.scopus.com/inward/record.url?scp=85160906226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85160906226&partnerID=8YFLogxK
U2 - 10.1093/noajnl/vdad017
DO - 10.1093/noajnl/vdad017
M3 - Article
C2 - 37025756
AN - SCOPUS:85160906226
SN - 2632-2498
VL - 5
JO - Neuro-Oncology Advances
JF - Neuro-Oncology Advances
IS - 1
M1 - vdad017
ER -